Laiyi Chua

533 total citations
22 papers, 385 citations indexed

About

Laiyi Chua is a scholar working on Physiology, Immunology and Surgery. According to data from OpenAlex, Laiyi Chua has authored 22 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 6 papers in Immunology and 5 papers in Surgery. Recurrent topics in Laiyi Chua's work include Alzheimer's disease research and treatments (7 papers), Diabetes Treatment and Management (5 papers) and Statistical Methods in Clinical Trials (5 papers). Laiyi Chua is often cited by papers focused on Alzheimer's disease research and treatments (7 papers), Diabetes Treatment and Management (5 papers) and Statistical Methods in Clinical Trials (5 papers). Laiyi Chua collaborates with scholars based in United States, Singapore and United Kingdom. Laiyi Chua's co-authors include John R. Sims, Brian A. Willis, Sergey Shcherbinin, Paul Ardayfio, Mary Seger, Helle Linnebjerg, David E. Coutant, C. Steven Ernest, Xin Zhang and Danny Soon and has published in prestigious journals such as Diabetes Care, Journal of Investigative Dermatology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Laiyi Chua

19 papers receiving 377 citations

Peers

Laiyi Chua
Leila Shobab United States
Melanie Watson United States
A Alencar Brazil
Jörg Seebeck Germany
W. I. Bry United States
Maurice E. Fabiani Australia
Jérémy Brégeon France
Gregory W. Munson United States
Viera Habalová Slovakia
Yoji Kyotani Japan
Leila Shobab United States
Laiyi Chua
Citations per year, relative to Laiyi Chua Laiyi Chua (= 1×) peers Leila Shobab

Countries citing papers authored by Laiyi Chua

Since Specialization
Citations

This map shows the geographic impact of Laiyi Chua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laiyi Chua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laiyi Chua more than expected).

Fields of papers citing papers by Laiyi Chua

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laiyi Chua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laiyi Chua. The network helps show where Laiyi Chua may publish in the future.

Co-authorship network of co-authors of Laiyi Chua

This figure shows the co-authorship network connecting the top 25 collaborators of Laiyi Chua. A scholar is included among the top collaborators of Laiyi Chua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laiyi Chua. Laiyi Chua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gueorguieva, Ivelina, Kay Hoong Chow, Laiyi Chua, et al.. (2025). Donanemab exposure‐response in early symptomatic Alzheimer's disease. Alzheimer s & Dementia. 21(7). e70491–e70491. 5 indexed citations
2.
Bhattachar, Shobha, Lai Tham, Li Yan, et al.. (2025). Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial. Diabetes Obesity and Metabolism. 27(11). 6460–6469.
3.
Chua, Laiyi, et al.. (2025). Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies. Clinical and Translational Science. 18(8). e70320–e70320. 1 indexed citations
4.
Mullins, Garrett R., Paul Ardayfio, Ivelina Gueorguieva, et al.. (2025). Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(3). e70149–e70149.
5.
Otani, Yuki, et al.. (2024). Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis. CPT Pharmacometrics & Systems Pharmacology. 14(3). 474–485.
6.
Friedrich, Stuart, et al.. (2024). Mirikizumab Exposure–Response Relationships in Patients with Moderately‐to‐Severely Active Ulcerative Colitis in Randomized Phase II and III Studies. Clinical Pharmacology & Therapeutics. 116(2). 435–447. 3 indexed citations
7.
Gueorguieva, Ivelina, Brian A. Willis, Laiyi Chua, et al.. (2023). Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(2). e12404–e12404. 14 indexed citations
8.
Gueorguieva, Ivelina, Brian A. Willis, Laiyi Chua, et al.. (2023). Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease. Clinical Pharmacology & Therapeutics. 113(6). 1258–1267. 46 indexed citations
9.
Chua, Laiyi, et al.. (2023). Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies. Clinical Pharmacokinetics. 62(10). 1479–1491. 15 indexed citations
10.
Gueorguieva, Ivelina, Laiyi Chua, Kay Hoong Chow, et al.. (2023). Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease. Alzheimer s & Dementia. 19(S7). 1 indexed citations
11.
Gueorguieva, Ivelina, Laiyi Chua, Brian A. Willis, John R. Sims, & Alette M. Wessels. (2022). Disease progression model using the integrated Alzheimer's Disease Rating Scale. Alzheimer s & Dementia. 19(6). 2253–2264. 9 indexed citations
12.
Lowe, Stephen L., Brian A. Willis, Fanni Natanegara, et al.. (2021). Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 7(1). e12112–e12112. 88 indexed citations
13.
Reich, Kristian, Kimberley Jackson, Susan Ball, et al.. (2018). Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. Journal of Investigative Dermatology. 138(10). 2168–2173. 39 indexed citations
14.
Chigutsa, Emmanuel, Nieves Vélez de Mendizábal, Laiyi Chua, et al.. (2018). Exposure‐Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis. The Journal of Clinical Pharmacology. 58(11). 1489–1500. 11 indexed citations
15.
Fleisher, Adam, Stephen L. Lowe, Peng Liu, et al.. (2018). O1‐09‐01: SIGNIFICANT AND SUSTAINED FLORBETAPIR F18 UPTAKE REDUCTION IN PATIENTS WITH SYMPTOMATIC ALZHEIMER'S DISEASE WITH LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY. Alzheimer s & Dementia. 14(7S_Part_4). 6 indexed citations
16.
Zhang, Xin, Mary Seger, David E. Coutant, et al.. (2017). LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels. Clinical Pharmacology in Drug Development. 6(6). 556–563. 13 indexed citations
17.
Willis, Brian A., Laiyi Chua, Eric Siemers, et al.. (2017). [P1–042]: PLASMA PHARMACOKINETICS AND PHARMACODYNAMICS OF SOLANEZUMAB IN MILD AND MODERATE AD PATIENTS. Alzheimer s & Dementia. 13(7S_Part_5). 5 indexed citations
18.
Zhang, Xin, Laiyi Chua, C. Steven Ernest, et al.. (2017). Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis. CPT Pharmacometrics & Systems Pharmacology. 6(12). 804–813. 21 indexed citations
19.
Linnebjerg, Helle, Mary Seger, David E. Coutant, et al.. (2016). Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 19(1). 33–39. 23 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leila Shobab Breakdown of academic impact, for papers by Melanie Watson Breakdown of academic impact, for papers by A Alencar Breakdown of academic impact, for papers by Jörg Seebeck Breakdown of academic impact, for papers by W. I. Bry Breakdown of academic impact, for papers by Maurice E. Fabiani Breakdown of academic impact, for papers by Jérémy Brégeon Breakdown of academic impact, for papers by Gregory W. Munson Breakdown of academic impact, for papers by Viera Habalová Breakdown of academic impact, for papers by Yoji Kyotani
Rankless by CCL
2026